Latest Mitemcinal Stories
Tranzyme Pharma announced today the successful completion of a Phase I, placebo-controlled, single ascending dose study of its orally administered ghrelin agonist, TZP-102. TZP-102 is the second drug candidate from Tranzyme's internal R&D efforts to reach clinical development. It is a potent prokinetic agent initially being developed for the treatment of mild-to-moderate gastroparesis. The Phase I study showed that TZP-102 has excellent oral bioavailability in man and is safe and...
- Exultant; jubilant; triumphant; on the high horse.
- Tipsy; slightly intoxicated.